HIV-host interactions: implications for vaccine design by Haynes, B, Shaw, G, Korber, B, Kelsoe, G, Sodroski, J, Hahn, B, Borrow, P, McMichael, A

P04-26. Immunological tolerance prevents the expression of a broadly reactive neutralizing HIV-1 antibody by Kelsoe G, Liao H, Alam SM, Ouyang Y, Bouton-Verville H, Holl TM, Diaz M, Verkoczy L, Haynes BF

Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies by Haynes, BF, Wiehe, K, Borrow, P, Saunders, KO, Korber, B, Wagh, K, McMichael, AJ, Kelsoe, G, Hahn, BH, Alt, F, Shaw, GM

Immune perturbations in HIV-1–infected individuals who make broadly neutralizing antibodies by Moody, M, Pedroza-Pacheco, I, Vandergrift, N, Chui, C, Lloyd, K, Parks, R, Ogbe, A, Cohen, M, Liao, H, Gao, F, McMichael, A, Montefiori, D, Verkoczy, L, Kelsoe, G, Huang, J, Shea, P, Connors, M, Borrow, P, Haynes, B

Antibody lineages with evidence of somatic hypermutation persisting for >4 years in a South African subject with broad neutralizing activity by Moody M, Trama AM, Bonsignori M, Tsao C, Drinker MS, Gurley TC, Amos JD, Eudailey JA, Armand LC, Parks R, Lloyd KE, Wang S, Seo K, Lee J, Jackson KJ, Hoh R, Pham T, Roskin KM, Boyd SD, Fire AZ, Gray ES, Morris L, Liao H, Tomaras GD, Kepler TB, Kelsoe G, Haynes BF

An HIV-1 antibody from an elite neutralizer implicates the fusion peptide as a site of vulnerability. by van Gils, M, van den Kerkhof, T, Ozorowski, G, Cottrell, C, Sok, D, Pauthner, M, Pallesen, J, de Val, N, Yasmeen, A, de Taeye, S, Schorcht, A, Gumbs, S, Johanna, I, Saye-Francisco, K, Liang, C, Landais, E, Nie, X, Pritchard, L, Crispin, M, Kelsoe, G, Wilson, I, Schuitemaker, H, Klasse, P, Moore, J, Burton, D, Ward, A, Sanders, R